Farmacore

Farmacore is a Brazilian biotechnology company dedicated to the development of innovative biological products, primarily vaccines and immunotherapies. Based in the Supera Innovation Park in Ribeirão Preto, the company focuses on addressing high-impact infectious diseases and oncology through advanced recombinant protein technology. Farmacore is most notably recognized for its partnership with PDS Biotechnology and Blanver to develop Versamune-CoV-2FC, a COVID-19 vaccine candidate that utilizes a T-cell activating platform. The company's pipeline also includes a recombinant vaccine for tuberculosis and other immunotherapy projects. By integrating academic research with industrial application, Farmacore plays a vital role in strengthening Brazil's domestic biopharmaceutical capabilities.